The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Head and Neck Cancer
16Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Nov 2025, none posted yet
Counts until it's fixed
- +5.9
2 insiders sold shares within a month
Since Sep 22, 2026 · was worth 10, fading over time
Worry score16
Score over time
- Stage
- Phase 3
- Patients
- 487 (final count)
- Started
- Dec 12, 2020
- Main results expected
- Nov 2, 2025
- Fully finished
- Nov 2, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Overall survival will be measured from time of randomization until death from any cause. The analysis will occur when all patients have been randomized and followed for 12 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-11-02, no fading
- insider_selling_cluster: base 10, now 5.9, since 2026-09-22, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04338399 · record last updated 2025-11-17 · checked 2026-11-09 06:30 UTC